18m
Seattle biotech looks to raise up to $288 million amid plans to spin out immune medicine business
The company said in a regulatory filing that separating its two business lines "would enable each to pursue its distinct ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results